Roche sänker budet på Genentech

I juli ifjol var budet 89 dollar per aktie. Då sa Genentechs styrelse nej tack. Nu meddelar läkemedelsjätten att man sänker budet och vänder sig direkt till småägarna.

We are poor lobbyists

I doubt there has ever been a really well thought out Scandinavian campaign with intentions to really change attitudes among both the public and politicians.

Young, bright and committed to labtech

Ghazal Voghoui recently bought her first apartment and finally settled in Stockholm again. Last year, she finished her law studies and she is relieved to be bac...

With their hands on the legal levers

It is wonderful news for the Scandinavian scientific community. At the end of May it stood clear that Lund will host to the European Spallation Source.

Time to save for survival

The future is bright for the biotech industry. However, the companies need to cut costs immediately if they want to survive the rough economic times.

Sales Representative, Applied Biosystems

International models among science parks

Science parks have become a part of modern communities. With science parks in Oxford, Cambridge and Nice setting good examples, a special potential emerged. Cou...

Ambassador program makes MVA big in Japan

The first ambassadors of the Medicon Valley Ambassador Programme have only worked in each other's countries for six months. But they have already made a signifi...

The winner of the race

She learned how to work hard at an early age and her devotion has certainly paid off. Whether it is field running or running a company, the key to success is fo...